title: [Initial results of proton therapy in choroidal melanoma at the d'Orsey Center for Proton Therapy; the first 464 cases].
abstract: OBJECTIVE
  Retrospective analysis of the treatment of choroidal melanoma with protontherapy at the Centre de protonthérapie d'Orsay, France.
  
  
  METHODS
  Between September 1991 and September 1995, 612 patients presenting with choroidal melanoma were treated by protontherapy in Orsay. Following initial management of the first 464 patients, results were analyzed, as were results after a 1-year follow-up for 305 patients, a 2-year follow-up for 169 patients, and a 3-year follow-up for 59 patients.
  
  
  RESULTS
  Univariate analysis showed that the actuarial local recurrence rate was 5%, the 3-year survival rate 88%, and the overall metastasic rate 5%. The initial tumor volume was the most significant predictive factor for visual results and metastases. Multivariate analysis revealed that visual results were significantly related to the initial tumor volume, initial retinal detachment, and total dose delivered to the optic nerve and macula.
  
  
  CONCLUSIONS
  Protontherapy of choroidal melanoma allows in most cases conservation of the eye without modification of survival. Visual results mainly depend on the site and size of the tumor.
authors.affiliation: Centre de protonthérapie d'Orsay, BP 65, France.
authors.forename: L
authors.initials: L
authors.lastname: Desjardins
authors.forename: C
authors.initials: C
authors.lastname: Levy
authors.forename: F
authors.initials: F
authors.lastname: d'Hermies
authors.forename: E
authors.initials: E
authors.lastname: Frau
authors.forename: P
authors.initials: P
authors.lastname: Schlienger
authors.forename: J L
authors.initials: JL
authors.lastname: Habrand
authors.forename: H
authors.initials: H
authors.lastname: Mammar
authors.forename: L
authors.initials: L
authors.lastname: Schwartz
authors.forename: A
authors.initials: A
authors.lastname: Mazal
authors.forename: S
authors.initials: S
authors.lastname: Delacroix
authors.forename: C
authors.initials: C
authors.lastname: Nauraye
authors.forename: R
authors.initials: R
authors.lastname: Ferrand
authors.forename: B
authors.initials: B
authors.lastname: Asselain
mesh_terms: D002830:Choroid Neoplasms / Q000453:epidemiology / Q000473:pathology / Q000532:radiotherapy*; D015353:Eye Enucleation; D005602:France / Q000453:epidemiology; D005901:Glaucoma / Q000209:etiology; D006801:Humans; D008545:Melanoma / Q000453:epidemiology / Q000473:pathology / Q000532:radiotherapy*; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local; D011522:Protons; D011879:Radiotherapy Dosage; D011882:Radiotherapy, High-Energy / Q000009:adverse effects / Q000379:methods*; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome; D014792:Visual Acuity / Q000528:radiation effects
chemical_list: D011522:Protons